.Attribute Medicine, Posted online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA study, after a mean follow-up of 11 months, individuals with metastatic gastrointestinal cysts who received biomarker-matched therapies based on distributing lump DNA profiling revealed a more significant clinical benefit than those getting unrivaled treatment.